Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rongqingbaohuashuan powder plus amlodipine in hypertension with carotid plaque
ChiCTR2200065430Phase 2Not yet recruiting
- Sponsor
- Qilu Hospital of Shandong University
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of Rongqingbaohuashuan in hypertension (HTN) and Carotid artery disease (CAD) (2 arms), sponsored by Qilu Hospital of Shandong University. Primary endpoints: Blood pressure and Carotid plaque. Planned start Nov 2022; status: not yet recruiting.
02
Drugs
Rongqingbaohuashuan
03
Conditions
hypertension (HTN)Carotid artery disease (CAD)
Beyond the preview
Go deeper on ChiCTR2200065430.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200065430.